Home / Stock ratings / Healthcare Stocks / ABT

Stock rating · Pharmaceutical Preparations

Abbott Laboratories (ABT) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Abbott Laboratories 53 out of 100 (Promising). Its highest factor score is risk-adjusted profile at 75, and its lowest is catalyst setup at 24.

MELANY ratingRated 2026-11-20

ABT · composite score

53/100
Promising
Nov 20
Rating date
Live price in the app →
Quality50
Momentum55
Risk-adjusted75
Source basis SEC filings and live market dataDated snapshot

About Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Its products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, adult nutritional liquids, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment, and it derives roughly 60% of sales outside the United States.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why ABT scores 53/100

ABT's 8 factor scores run from 24 to 75, and 4 of them sit above its composite of 53. Here is how ABT breaks down.

Valuation55/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • Forward P/E 17.3x, earnings growth accelerating
Business quality50/100

Margins, returns on capital, and balance-sheet strength.

Price momentum55/100

Direction and relative strength of the recent share-price trend.

Earnings track record51/100

History of beating or missing estimates, and where estimates are heading.

Analyst sentiment73/100

What Wall Street price targets and revisions are signalling.

Catalyst setup24/100

Near-term events that could move the stock.

Risk-adjusted profile75/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How ABT compares

As of November 20, 2026, Abbott Laboratories is tied for 19th of 20 in Healthcare Stocks, where the average score is 62.

All stock rating pages.

Key risks for ABT

  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt

Sector and theme context

Abbott Laboratories sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds ABT's momentum and catalyst factors above.

ABT trade plan (Pro)

MELANY has a full position plan for Abbott Laboratories: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates ABT

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Abbott Laboratories's 53/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about ABT

Is Abbott Laboratories (ABT) a buy?

As of 2026-11-20, MELANY rated Abbott Laboratories Promising with a composite score of 53/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does ABT rank against similar companies?

As of November 20, 2026, Abbott Laboratories is tied for 19th of 20 in MELANY's Healthcare Stocks list, where the average score is 62. Among the other names in the list, the highest scores belong to REGN (74) and MDT (71).

Should I buy Abbott Laboratories stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Abbott Laboratories (ABT) Promising with a composite of 53/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the ABT stock price forecast?

MELANY does not publish price targets or forecasts for ABT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 53/100 across eight factors for Abbott Laboratories, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for ABT as of 2026-11-20: its analyst sentiment factor is 73/100, and its price momentum factor is 55/100.

Is ABT stock overvalued or undervalued?

MELANY's valuation factor currently reads 55/100 for Abbott Laboratories, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ABT's read.

What price should I buy ABT at?

Rather than chasing the current price, MELANY computes a smart entry zone for ABT: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying ABT stock?

The top risks MELANY currently flags for Abbott Laboratories: Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Abbott Laboratories a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 50/100 for Abbott Laboratories, and earnings track record, at 51/100. The 53/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will ABT stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 55/100 for ABT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this ABT rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores ABT as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, ABT included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.